MAXCYTE, INC. - 8-K Filing
MaxCyte raises full-year revenue guidance to $34M, citing strong Q3 performance and SPL program milestones (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $MXCT
Read the full article at SEC EDGAR
Part of the story JOHNSON & JOHNSON - 8-K Filing (37 articles)